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A 2 day symposium entitled ‘‘International Centennial Meeting on
Pseudoxanthoma Elasticum’’ was held in Bethesda, Maryland, on
November 6 and 7, 1997. The meeting was planned by a committee
consisting of the authors of this report and was chaired by Dr. Jouni
Uitto, Department of Dermatology and Cutaneous Biology at Jefferson
Medical College. Ms. Sharon Terry, President of PXE International,
served as meeting coordinator. This meeting was attended by about
50 scientists and physicians from nine different countries, as well as
several representatives of the patient advocacy organizations.
This meeting was considered extremely timely for several reasons.
First, the initial definitive description of pseudoxanthoma elasticum
(PXE) appeared in the medical literature just about 100 years ago, in
1896, and clearly delineated this disorder as an entity distinct from
xanthomas (Darier, 1896). Second, 5 years had passed since the previous
PXE symposium that was held at Jefferson Medical College in 1992
(Christiano et al, 1992). Finally, the progress in understanding various
facets of PXE has advanced tremendously during the past 5 years, and
in fact, the candidate gene underlying the majority of cases with PXE
has been recently mapped to a distinct chromosomal region in the
human genome at 16p13.1 (Struk et al, 1997; van Soest et al, 1997).
The keynote speaker of the meeting was Dr. Francis Collins, Director
of the National Human Genome Research Institute, National Institutes
of Health. Dr. Collins highlighted the advances of the human genome
project that, he reported, is ‘‘on time and on budget.’’ The goal of this
project is to complete the sequencing of the entire human genome by
year 2005 (Collins, 1997). It is clear that these efforts are making a
major impact on elucidation of genetic defects in heritable diseases,
such as PXE. Dr. Collins also emphasized the importance of collabora-
tions with regard to studies on such relatively rare diseases. Dr. Collins
further emphasized the fact that genetics has become the central
science of medicine, with major implications for molecular diagnostics,
prognostication, and genetic counselling. Identification of candidate
genes and elucidation of mutations in heritable diseases form the basis
for prenatal testing in families at risk for recurrence, and ultimately
cure of these diseases in the form of gene therapy. At the same time,
the progress in understanding the genetic basis of both monogenic as
well as multifactorial diseases has raised several issues in the public
policy arena, with the recognition of potential for genetic discrimina-
tion. Clearly, solutions for such issues have to be developed in order
to provide maximum benefit from the latest genetic discoveries to the
affected individuals and their families.
The ensuing symposium featured 21 internationally recognized
scientists whose presentations described the pathophysiology and genet-
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ics of PXE and reviewed, in considerable detail, the clinical manifesta-
tions of the disease. The following is a summary of these presentations
in the light of the identification of at least one major genetic locus for
this heritable elastic tissue disorder.
GENETICS OF PXE
PXE is a systemic heritable connective tissue disorder primarily affecting
the elastic tissue network in the body (Neldner, 1988). The precise
incidence of PXE is unclear, its cause is unknown, and the underlying
molecular gene defect remains to be delineated.
PXE demonstrates marked clinical and genetic heterogeneity (Pope,
1975; Neldner, 1988). The clinical variability is demonstrated by the
fact that the involvement of the three major organ systems being
affected, i.e., skin, eyes, and the cardiovascular system, is evident in
some patients, whereas in others only a limited involvement of one of
these organ systems can be found. For example, the presence of the
disease may be suggested only by ophthalmologic examination, which
may reveal the angioid streaks, without any further evidence of the
disease. In the absence of information on a specific gene defect, this
clinical variability raises critical questions concerning the mode of
inheritance and accurate diagnosis (Lebwohl et al, 1994). Although
genetic heterogeneity has been suggested in previous publications, and
the existence of autosomal dominant and autosomal recessive patterns
has been documented (Pope, 1974a, b, 1975), it appears that the
majority of cases are sporadic. Among the families demonstrating a
discernible mode of inheritance, autosomal recessive inheritance appears
to be more common than autosomal dominant. This has clear implica-
tions for genetic counselling of families at risk for PXE regarding the
possibility of an affected child in subsequent pregnancies and in future
generations; however, assignment of an unequivocal inheritance pattern
in most families, in the absence of genetic markers for carrier detection,
is currently difficult. Furthermore, the elucidation of inheritance is
complicated by clinical variability and late onset of the disease, the
mean age of onset being µ13 years. It was suggested that the disease
may be primarily autosomal recessive, with heterozygous carriers
demonstrating minimal, yet suggestive, signs of PXE. Alternatively,
the disease could be autosomal dominant with incomplete penetrance.
Consequently, the affected families should be counselled conservatively
with the worst case scenario estimates of the risk.
The progress made towards improved understanding of the genetic
basis of PXE was highlighted by the fact that a major PXE locus has
been recently mapped to the short arm of human chromosome 16,
spanning region 16p13.1 (Struk et al, 1997; van Soest et al, 1997).
Although the gene for PXE has not been identified as yet, haplotype
analyses spanning the region on chromosome 16p13 have suggested
that the major mode of inheritance is autosomal recessive. On the
other hand, it was suggested that ocular and cutaneous lesions may be
inherited primarily in an autosomal recessive fashion, whereas vascular
problems may be inherited in an autosomal dominant fashion, resulting
from differential penetrance of the gene defect in different tissues.
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Human chromosome 16 consists of 98 Mb, demonstrates 24 cytogen-
etic bands, and has at least five fragile sites. Approximately 300 genes
are known to be encoded by chromosome 16 and some 35 diseases
are associated with abnormalities in these genes (Doggett et al, 1995).
Although the region harboring the PXE gene is not particularly rich
in expressed genes, several genes within the interval have been
identified. These include members of the multiple drug resistance
gene, myosin heavy chain polypeptide 11, and a calmodulin dependent
phosphodiesterase. In addition, a polymorphic CCG repeat fragile site
(FRA16 A) is within the interval. Mutations in any of these candidate
genes would be unlikely to explain the pleiotropic manifestations noted
in patients with PXE. Clearly, examination of additional families by
utilizing informative markers flanking the PXE locus is required for
identification of additional informative meioses in order to narrow the
candidate gene interval. These efforts are currently being combined
with continued mapping and sequencing of the corresponding region
of chromosome 16, as well as the use of complementary approaches,
including differential display. Using other heritable diseases as examples,
one could predict that the actual gene responsible for PXE mutations
residing on chromosomal region 16p13.1 will be identified in the near
future. At the same time, it was noted that identification of the gene
may well be only the beginning of a long journey towards understanding
the mechanisms leading to PXE. Again, using several other heritable
diseases as examples, such as cystic fibrosis and neurofibromatosis, it is
conceivable that enormous efforts towards biochemical and cell biologic
characterization of the gene products and their functions will be
required to disclose how these gene defects result in the clinical signs
of PXE.
ELASTIC FIBERS AND PXE
The pathology of PXE affects elastic fibers in several tissues, including
skin, Bruch’s membrane of the eye, and the arterial blood vessels. The
histopathologic hallmark of PXE in the skin is accumulation of
pleiomorphic, ‘‘elastotic’’ material in the mid-dermis. The morphology
of these structures is clearly perturbed, suggesting functional alterations
in the elastic fibers. Furthermore, a diagnostic feature of PXE is
calcification of these elastic structures, which can be demonstrated by
special histopathologic stains or by transmission electron microscopy
of the skin. In addition, elastic structures in the arterial blood vessels
as well as within the Bruch’s membrane can become calcified.
It is now clear that elastic fibers consist of several multifunctional
proteins (Mecham and Heuser, 1991; Rosenbloom, 1996). The major
component is elastin, a well characterized connective tissue protein.
Specific mutations in the elastin gene have been shown to underlie
heritable diseases, including Williams syndrome, supravalvular aortic
stenosis, and some forms of cutis laxa. In PXE, the primary genetic
lesion does not reside in the elastin gene (ELN) that has been mapped
to the long arm of chromosome 7 (Fazio et al, 1991).
Elastin is associated with multiple microfibrillar proteins that are
now known to represent distinct groups, including fibrillins (FBN1
and FBN2), latent transforming growth factor-β binding proteins,
microfibril associated glycoproteins, and others (Rosenbloom, 1996).
Many of these proteins contain epidermal growth factor like domains
and multiple calcium binding sites. Thus, any of the corresponding
genes could potentially serve as a candidate gene for mutations in
PXE; however, chromosomal mapping of many of these genes has
thus far indicated loci different from 16p, thus excluding them as the
primary site for mutations in PXE (Uitto and Rosenbloom, 1998). It
should be noted, however, that some of the microfibrillar proteins
have not been cloned as yet, and consequently the chromosomal
locations of the corresponding genes are currently unknown.
As indicated above, a diagnostic feature of PXE is calcification of
the elastic structures (Baccarani Contri et al, 1996). Some mechanistic
insight into these abnormal calcifications has been provided by recent
studies on extracellular mineral binding Gla proteins, a small family
consisting at this point of osteocalcin and matrix Gla protein. Although
the precise function of these proteins is still somewhat obscure,
emerging evidence suggests that they play a role in endochondral
ossification (Luo et al, 1995); however, it appears that their presence may
be necessary to prevent abnormal calcification. The latter conclusion was
drawn from studies examining knockout mice with ablated matrix Gla
protein gene. A dramatic feature of these animals was extensive
calcification of elastic structures in a variety of tissues, including arterial
blood vessels (Luo et al, 1997). Again, human matrix Gla protein has
been mapped to a chromosomal locus 12p, excluding it as a major
candidate gene for PXE.
As noted from clinical, morphologic, and ultrastructural studies,
changes in the extracellular matrix of connective tissue, primarily elastic
tissues, is the pathologic hallmark of PXE; however, mapping of the
known extracellular matrix genes has revealed loci distinct from 16p.
Thus, the involvement of elastic tissues in PXE could be explained by
two different predictions. First, PXE could be due to genetic alterations
in a gene encoding a yet to be discovered extracellular matrix
component of the elastic tissues. In this context, it should be noted
that genes encoding certain extracellular matrix proteins (e.g., emilin;
Bressan et al, 1993) have not been cloned as yet and their chromosomal
location is unknown. The second possibility is that the changes seen
in elastic structures, including morphologic alterations and calcification,
are secondary to a primary defect in a gene that does not encode an
elastic fiber component directly. Nevertheless, understanding of the
biochemistry and cell biology of elastic fibers is critical for further
understanding of the pathomechanisms of PXE. Delineation of the
structural features and metabolic pathways leading to elastic fiber
assembly may also provide a pharmacologic perspective with the
potential to interfere with the deposition of abnormal material in the
skin and other affected tissues in PXE.
CLINICAL FEATURES OF PXE
PXE primarily affects skin, eyes, and the blood vessels, with considerable
morbidity. One of the intriguing features, however, is considerable
phenotypic variability that can be both intra- and interfamilial. The
intrafamilial variability could be explained, to a certain extent, by the
mode of inheritance. For example, in the autosomal recessive families,
heterozygous carriers could possibly show partial manifestations of the
disease. This situation could be somewhat analogous to Alport’s
syndrome, an X-linked renal disorder in which the heterozygous
carrier mother often demonstrates subtle clinical manifestations. Altern-
atively, the autosomal dominant inheritance would result in a relatively
mild disease in individuals with a mutation in one allele only, whereas
individuals homozygous or compound heterozygous for mutations in
both alleles would manifest with a more severe phenotype. This
intrafamilial heterogeneity also raises the question of diagnostic criteria
for PXE (Lebwohl et al, 1994). It was agreed that angioid streaks in
an individual without family history are not sufficient for diagnosis of
PXE. At the same time, the presence of angioid streaks in an individual
with a family history of PXE, particularly coupled with demonstration
of calcified elastic fibers in the skin, is sufficient for diagnosis even in
the absence of overt cutaneous manifestations.
The interfamilial phenotypic variability perhaps is best explained by
genotype/phenotype correlations due to allelic heterogeneity. The
latter possibility can obviously be addressed only after identification of
specific mutations and analysis of an extended mutation database,
coupled with careful clinical examination of the affected individuals.
An intriguing possibility is that the genetic background of the affected
individuals may alter the expression of the mutated gene. This would
also raise the possibility of modifier genes that might alter the expression
of the gene primarily affected.
Another set of factors modifying the disease severity may relate to
nutritional, environmental, and life-style variables that should be
considered during the evaluation of patients with PXE. These include,
for example, intake of drugs, vitamins, hormones, and nutritional
supplements. It is clear that avoidance of aspirin and nonsteroidal anti-
inflammatory drugs, which result in prolonged bleeding times, can be
beneficial to the patients with PXE during episodes of hemorrhaging.
Similarly, cigarette smoking, which can worsen intermittent claudica-
tion, is a clear-cut risk factor in PXE; however, the influence of
other drugs or dietary variables is less certain. For example, does
postmenopausal hormone replacement therapy alter the clinical severity
842 UITTO ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
of PXE? Can pregnancy affect the severity of PXE? Are vitamin D
supplementation and excessive calcium intake risk factors for PXE?
Does hyperlipidemia accelerate the clinical involvement of coronary
arteries? Although individual physicians may have recommendations
for patients with PXE in these areas, clinical data in support of such
recommendations are largely lacking. In the area of prevention, avoiding
head trauma to avoid retinal hemorrhaging certainly makes sense
in children with PXE; however, the value of laser treatment for
neovascularization of retina is still unclear. These kinds of issues should
be addressed by controlled clinical trials that should incorporate novel
technologies to evaluate consequences of PXE and treatment attempts.
Finally, the efficacy of various treatment modalities as well as environ-
mental influences could be potentially tested in animals if the ongoing
search for animal models for PXE is to be successful.
RECOMMENDATIONS ON FUTURE RESEARCH
At the end of the meeting, a panel was convened to identify areas of
importance in basic research and clinical emphasis in relation to PXE.
Panel members concurred with the following recommendations. With
regard to research, the following areas were considered of the highest
importance.
1 Intensification of efforts to identify the gene or genes that harbor
mutations causing PXE, through the use of state-of-the-art technolo-
gies. These efforts should take advantage of the human genome project,
as well as other efforts to characterize gene loci within the candidate
region on chromosome 16p.
2 Addressing phenotype/genotype correlations by examination of a
mutation database, in the future, in the context of clinical variability.
3 Delineation of disease mechanisms by continued investigation of
normal composition, biosynthesis, and assembly of elastic structures
with an emphasis on structure–function relationships.
4 Development of clinical studies to identify confounding variables
that may modify the severity and presentation of the disease, including
hormonal aspects, dietary regiments, and blood lipid profiles. The
importance of this approach is emphasized by the fact that identification
of risk factors may provide opportunities to interfere with development
of complications and progression of the disease through pharmacologic
intervention and life-style changes.
5 Development of outcome studies regarding the efficacy of specific
treatment modalities. An example of such a study is the use of lasers
to treat retinal neovascularization.
6 Continued development of animal models of PXE, both through
generation of transgenic animals and through screening of naturally
occurring mutant mouse strains.
7 Intensified efforts to secure continued research funding from national
sources to study the basic biology and pathophysiology of the skin,
eyes, and cardiovascular system in the context of PXE.
8 Vigorous efforts to gain further public support for research on PXE
and other heritable connective tissues disorders, through interactions
with the Coalition of Heritable Connective Tissue Disorders
(CHCTD), the Coalition of Patient Advocates for Skin Disease
Research (CPASDR), the National Organization for Rare Diseases
(NORD), and others.
In the clinical area of PXE, the following issues should be emphasized.
1 Identification of additional patients and families for increased sample
collection of clinical material, through the PXE International Blood
and Tissue Bank, for distribution to all qualified researchers.
2 Refinement of diagnostic criteria to identify individuals affected
by PXE.
3 Careful examination of the pattern of inheritance, particularly
after identification of the gene mutations, in families with clinical
manifestations of PXE.
4 Continued monitoring of the evolution of the disease in individual
patients to provide a database for prognostic indicators.
5 Continued fostering of international exchange of information and
research material to enhance studies on PXE. This includes organizing
workshops, similar to this one, at regular intervals.
This meeting was sponsored by PXE International Inc., and supported by the National
Institute of Arthritis and Musculoskeletal and Skin Diseases, Office of Rare Diseases,
and Office of Pediatric Research Initiative of the National Institutes of Health through
a Grant 1R13 AR44826–01.
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